Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The OCT2/MATE1/MATE2-K transport system is a critical pathway for the renal secretion of organic cations, consisting of the Organic Cation Transporter 2 (OCT2/SLC22A2) and the Multidrug and Toxin Extrusion proteins 1 and 2-K (MATE1/SLC47A1 and MATE2-K/SLC47A2) [1, 12]. OCT2 is localized to the basolateral membrane of renal proximal tubule cells, where it facilitates the uptake of cationic drugs and endogenous metabolites from the blood into the cell [1, 8]. MATE1 and MATE2-K are expressed on the apical membrane and mediate the efflux of these substances into the tubular lumen for excretion in the urine [8, 10]. This coordinated transport is a major determinant of the pharmacokinetics and renal clearance of numerous drugs, most notably the anti-diabetic agent metformin and the chemotherapeutic cisplatin [6, 16]. Inhibition of these transporters by "perpetrator" drugs, such as cimetidine or dolutegravir, can lead to significant drug-drug interactions, increasing the systemic exposure or local tissue toxicity of "victim" drugs [2, 12]. Furthermore, the differential transport of platinum-based agents by this system explains the specific nephrotoxicity of cisplatin, which is an OCT2 substrate but a poor MATE substrate, leading to its accumulation in renal cells [6, 16]. Genetic polymorphisms in the genes encoding these transporters (SLC22A2, SLC47A1, SLC47A2) can also significantly influence drug response and toxicity profiles [4, 15]. Consequently, this pathway is a key focus of regulatory guidelines for evaluating the safety and efficacy of new molecular entities [2, 5].
Inhibition of renal tubular secretion of organic cations through competitive or non-competitive binding to basolateral (OCT2) or apical (MATE1/2-K) transporters, thereby altering the pharmacokinetics and tissue distribution of substrate drugs [1, 2, 12].
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Organic cation transporter 2, Multidrug and toxin extrusion protein 1, and Multidrug and toxin extrusion protein 2-K (OCT2/MATE1/MATE2-K).